This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of nab-paclitaxel/gemcitabine combined with nimotuzumab sequential irreversible electroporation ablation for locally advanced pancreatic cancer. The main endpoint is overall survival (OS).
1. Age 18-75 years old, gender unlimited;
2. Histologically or cytologically confirmed pancreatic cancer;
3. Confirmed as locally advanced pancreatic cancer by CT/MRI imaging, with no evidence of distant metastasis;
4. No prior chemotherapy or other tumor systemic therapy;
1. Refuse chemotherapy or surgery;
2. Other part (e.g. peritoneum, lung, bone, brain) metastasis;
3. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
4. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP>160mmHg or DBP>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;